Parenting support for families dealing with advanced cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a parenting support intervention designed for families coping with metastatic or recurrent solid tumors. The study aims to assess the acceptability and feasibility of the intervention, which includes educational materials and videoconference sessions for both parents and their spousal caregivers. Participants will be randomized into two groups: one receiving the intervention and the other receiving standard care. The trial also seeks to gather qualitative insights on the experiences of participants to inform future research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must (1) be diagnosed with a metastatic or locally recurrent solid malignant tumor and on active treatment; (2) be at least 18 years old; (3) have at least one dependent child between the ages of 4 and 17 and currently living with the parent; (4) be able to provide informed consent and (5) have a spousal caregiver over the age of 18 who co-parents the child(ren) (i.e. share custody) and is willing and able to consent to participate.\*

Exclusion Criteria:

* Participants and caregivers who do not read and speak English and who do not have access to the internet.

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Kathrin Milbury — M.D. Anderson Cancer Center
• Study coordinator: Kathrin Milbury
• Email: kmilbury@mdanderson.org
• Phone: 713-745-2868

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting how tumors respond to immune therapies using a live diagnostic platform

  This study is testing a new way to predict how well immune therapies will work for patients with different types of solid tumors, including early-stage and metastatic cancers.

  Recruiting at 3 sites Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT06349642

• Combining axatilimab, retifanlimab, and paclitaxel for advanced solid tumors

  This study is testing a new combination of three medications to see if they can help people with advanced solid tumors feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 OHSU Knight Cancer Institute · Portland, Oregon · NCT06320405

• Evaluating TAK-243 for advanced cancer treatment

  This study is testing a new drug called TAK-243 to see if it can safely help people with advanced cancer by looking at how it affects their tumors and overall health.

  Recruiting Phase 1 National Cancer Institute (NCI) · Bethesda, Maryland · NCT06223542

• Targeted therapy for advanced solid tumors based on genetic testing

  This study is testing whether matching patients with advanced solid tumors to specific treatments based on their genetic makeup can improve their outcomes when standard options have failed.

  Recruiting at 437 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 483 other locations · NCT05564377

• Combining talazoparib with palbociclib, axitinib, or crizotinib for advanced solid tumors

  This study is testing a new combination of drugs for people with advanced solid tumors to see which mix works best and is safest to use.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT04693468

• Gene modified immune cells for treating advanced melanoma and metastatic solid tumors

  This study is testing if modified immune cells can safely target and attack advanced melanoma and other solid tumors in patients after they receive chemotherapy.

  Recruiting at 3 sites Phase 1 Stanford University · Duarte, California and 2 other locations · NCT04119024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.